DHR vs MTD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and MTD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and MTD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

Mettler-Toledo International Inc. (NYSE: MTD) designs, manufactures, and services precision instruments used to weigh, measure, and analyze materials. It reports across three segments: Laboratory (roughly 55% of sales, including balances, pipettes, pH meters, titrators, thermal analysis, and automated chemistry serving pharma, biotech, and academic customers), Industrial (roughly 40%, including industrial weighing, terminals, and automated product-inspection systems like metal detectors and X-ray for food and manufacturing lines), and Food Retail (roughly 5%, weighing and labeling systems for supermarkets). The business is geographically diversified, with the Americas around 37% of sales, Europe around 27%, China around 16%, and the rest of the world the remainder. A large share of revenue is recurring service and consumables, which cushions the equipment cycle, and the company holds a dominant position (over half) of the global market for laboratory balances.

Full MTD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
• MTD drivers: Wide moat and pricing power in precision instruments; Recurring service and consumables revenue.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 41x on GAAP earnings with a forward P/E near 25x as of October 16, 2026), leaving little room for disappointment. For MTD, mettler-Toledo carries a premium valuation (a trailing P/E around 36x as of October 2026, after a sharp rally), so any disappointment in growth or margins can compress the multiple sharply.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DHR if you believe its drivers more; MTD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and MTD guides.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, and growth picked up to about 5.5% in the second quarter of 2026. After a 29% three-month rally, the stock trades near 25x forward earnings and about 23x EV/EBITDA, the upper part of its usual premium range, with consensus EPS of about $8.51 for 2026 and $9.30 for 2027. The 22 analysts tracked by Yahoo Finance hold a strong buy consensus with a mean target near $244, close to the current price; figures are approximate and as of October 16, 2026.

MTD. After a 26% three-month rally, Mettler-Toledo trades at about 36x trailing and 32x forward earnings, above the multiple of roughly 30x it carried in mid-2026 and above the analyst mean target of about $1,529. It pays no dividend, returning capital through buybacks that steadily reduce the share count (the balance sheet carries about $2.1 billion of debt and little cash as a result). The valuation prices in continued mid-single-digit sales growth converting into high-single-digit to low-double-digit EPS growth.

Headline figures (approximate, October 2026): DHR shows revenue (ttm) ~$25.1B; Q2 2026 ~$6.26B (+5.5%), q2 2026 adj. eps $1.94 vs ~$1.84 estimate, margins (ttm) ~58.8% gross, ~19.8% operating, ~16.0% net, net income (ttm) ~$3.99B (GAAP EPS ~$5.61); MTD shows revenue (ttm) ~$4.1 billion, revenue growth (latest quarter, yoy) ~+4.5%, net income (ttm) ~$906 million, gross / operating margin ~60% / ~31%.

DHR and MTD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DHR and MTD exposure against your real portfolio. It is not an investment adviser.